{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Falade-Nwulia O"],"funding":["NCATS NIH HHS","NIAID NIH HHS","NHLBI NIH HHS"],"pagination":["991-993"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8101059"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(6)"],"pubmed_abstract":["Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB."],"journal":["AIDS (London, England)"],"pubmed_title":["Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy."],"pmcid":["PMC8101059"],"funding_grant_id":["U01 AI035043","R01 AI116269","U01 HL146201","R03 AI096918","UL1 TR001881","P30 AI094189"],"pubmed_authors":["Thio CL","Falade-Nwulia O","Wolinsky SM","Seaberg EC","Snider AE","Rinaldo CR","Witt MD"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy.","description":"Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-04T10:16:17.263Z","creation":"2025-04-04T10:16:17.263Z"},"accession":"S-EPMC8101059","cross_references":{"pubmed":["33587444"],"doi":["10.1097/qad.0000000000002844","10.1097/QAD.0000000000002844"]}}